Lisata adds biopharma finance veteran Jeffrey Farrow to boardProactive Investors · Oct 15, 2026
Financial Survey: Lisata Therapeutics (NASDAQ:LSTA) vs. Dyadic International (NASDAQ:DYAI)Defense World · Oct 15, 2026
Lisata Therapeutics Appoints Jeff Farrow to Board of DirectorsGlobeNewsWire · Oct 14, 2026
Head to Head Analysis: GeoVax Labs (NASDAQ:GOVX) vs. Lisata Therapeutics (NASDAQ:LSTA)Defense World · Oct 11, 2026
Lisata Therapeutics wins new US patent for pancreatic cancer drugProactive Investors · Oct 8, 2026
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid TumorsGlobeNewsWire · Oct 8, 2026Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | – | -$0.32 | |
| May 14, 2026 | – | -$0.50 | |
| Mar 12, 2026 | -$0.51 | -$0.74 | Miss |
| Nov 6, 2025 | -$0.54 | -$0.49 | Beat |
| Aug 7, 2025 | -$0.65 | -$0.54 | Beat |
| May 8, 2025 | -$0.53 | -$0.55 | Miss |